Immuneering Net Income From Continuing Ops from 2010 to 2024

IMRX Stock  USD 2.08  0.02  0.95%   
Immuneering Corp Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2024. During the period from 2010 to 2024, Immuneering Corp Net Loss regression line of annual values had significance of  0.0003 and arithmetic mean of (18,591,358). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-51.6 M
Current Value
-49.1 M
Quarterly Volatility
17.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immuneering Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immuneering Corp's main balance sheet or income statement drivers, such as Net Interest Income of 3.5 M, Interest Income of 3.5 M or Depreciation And Amortization of 369.7 K, as well as many indicators such as Price To Sales Ratio of 207, Dividend Yield of 0.0 or PTB Ratio of 2.42. Immuneering financial statements analysis is a perfect complement when working with Immuneering Corp Valuation or Volatility modules.
  
Check out the analysis of Immuneering Corp Correlation against competitors.
For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.

Latest Immuneering Corp's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Immuneering Corp over the last few years. It is Immuneering Corp's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immuneering Corp's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Immuneering Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(18,591,358)
Coefficient Of Variation(95.88)
Mean Deviation14,716,074
Median(7,709,448)
Standard Deviation17,825,820
Sample Variance317.8T
Range43.9M
R-Value(0.80)
Mean Square Error120.5T
R-Squared0.65
Significance0.0003
Slope(3,208,096)
Total Sum of Squares4448.6T

Immuneering Net Income From Continuing Ops History

2024-49.1 M
2023-51.6 M
2022-50.5 M
2021-33.5 M
2020-17 M

About Immuneering Corp Financial Statements

Immuneering Corp investors use historical fundamental indicators, such as Immuneering Corp's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immuneering Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-51.6 M-49.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.